Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | GSK3B | P49841 | 10/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436553 | 0.77 | GSK3B (0.58) | PTPN1GSK3B | |
| SCHEMBL933642 | 0.77 | MAOA (0.46) | CYP1A2MAOAMAOB | |
| SCHEMBL933850 | 0.77 | GSK3B (0.41) | GSK3BHPGDCYP1A2MAOAMAOB | |
| SCHEMBL1293480 | 0.73 | PTPN1 (0.68) | PTPN1GSK3BHPGD | |
| SCHEMBL483190 | 0.72 | PTPN1 (0.56) | PTPN1GSK3BHPGD | |
| SCHEMBL15060475 | 0.72 | GSK3B (0.46) | PTPN1GSK3BHPGD | |
| SCHEMBL9939279 | 0.72 | CHEK1 (0.46) | HPGDMAOAMAOB | |
| SCHEMBL11482012 | 0.71 | PTPN1 (0.84) | PTPN1GSK3BHPGDCYP1A2 | |
| SCHEMBL23781126 | 0.71 | PTPN1 (0.56) | PTPN1GSK3BCYP1A2 | |
| SCHEMBL2696504 | 0.71 | PTPN1 (0.60) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | PTPN1 1415/4885GSK3B 447/4885HPGD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.